Treatment carryover impacts on effectiveness of intraocular pressure lowering agents, estimated by a discrete event simulation model

European Journal of Ophthalmology

Volumn 18, Issue 1, 2008, Pages 44-51

  Denis, P ^a   Le Pen, C ^b   Umuhire, D ^c   Berdeaux, Gilles ^d,e,f  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DAUPHINE   (France)

^c Aremis   (France)

^d Alcon France   (France)

^e University of Paris Cité   (France)

^f NONE   (France)

Author keywords

Glaucoma; Latanoprost; Ocular hypertension; Timolol; Travoprost

Indexed keywords

LATANOPROST; LATANOPROST PLUS TIMOLOL; PROSTAGLANDIN; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

EID: 39049173052     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800108     Document Type: Article

References (33)

1. Leske MV, Heijl A, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Acta Ophthalmol 2002; 120: 1268-79.
2. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130: 429-40.
3. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714-20.
4. Odberg T, Jakobsen JE, Hultgren SJ, et al. The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmol Scand 2001; 79: 121-4.
5. Odberg T, Jakobsen JE, Hultgren SJ, et al. The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmol Scand 2001; 79: 116-20.
6. Denis P, Launois R, Devaux M, Berdeaux G. Comparison of diurnal IOP control by latanoprost versus travoprost: results of an observational survey. Clin Drug Invest 2006; 26: 703-714.
7. Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006; 141 (Suppl): S28-33.
8. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140: 598-606.
9. Buchan JC, Siddiqui S, Gilmour D. Simplification of eye drop regimes helps reduce involuntary non-compliance with glaucoma treatment. Graefes Arch Clin Exp Ophthalmol 2006; 6 [Epub ahead of print].
10. Stewart WC, Konstas AG, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004; 20: 461-9.
11. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12: 393-8.
12. Hjelmgren J, Berggren F, Andersson D. Health Economics guidelines-Similarities, differences and some implications. Value Health 2001; 4: 225-50.
13. Varner P. Applying number-needed-to-treat (NNT) analysis to ophthalmic clinical trials. Optom Vis Sci 2006; 83: 919-30.
14. Weinstein MC. The cost of prevention. J Gen Intern Med 1990; 5 (Suppl): S89-92.
15. Coyle A, Drummond M. The economic burden of glaucoma in the UK-The need for a farsighted policy. Pharmacoeconomics 1995; 7: 484-9.
16. Knox FA, Barry M, McGowan B, O'Brien C. The rising cost of glaucoma drugs in Ireland 1996-2003. Br J Ophthalmol 2006; 90: 162-5.
17. Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma. 2001; 10: 184-91.
18. Oostenbrink JB, Rutten-van Molken MP, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 1999; 98: 285-99.
19. Calissendorff BM. Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand 2001; 79: 286-8.
20. Jonsson B, Krieglstein G. Primary open-angle glaucoma. Differences in international treatment patterns and costs. Ed. Isis. Oxford: Medical Media; 1999.
21. Kobelt-Nguyen G, Gerdtham UG, Aim A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998; 7: 95-104.
22. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004; 13: 283-90.
23. Hitzl W, Ortner C, Hornykewycz K, Grabner G, Reitsamer HA. Resource use and costs for a glaucoma screening program in Austria: an 8-year review: a cost-consequence analysis based on the Salzburg-Moorfields Collaborative Glaucoma Study. Eur J Ophthalmol 2006; 16: 92-9.
24. Walker JH, Buys Y, Trope G, Vicente C, Einarson TR, Covert D, Iskedjian M. Association between corneal thickness, mean intraocular pressure, disease stability and severity, and cost of treatment in glaucoma: a Canadian analysis. Curr Med Res Opin 2005; 21: 489-94.
25. Vicente C, Walker J, Buys Y, Einarson TR, Covert D, Iskedjian M. Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada. Curr Med Res Opin 2004; 20: 1245-51.
26. Iskedjian M, Walker J, Vicente C, Trope GE, Buys Y, Einarson TR, Covert D. Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. J Glaucoma 2003; 12: 456-62.
27. Denis Ph , Lafuma A, Khoshnood B, Mimaud V, Berdeaux G. Comparison of prostaglandin topical treatments for glaucoma in monotherapy: a meta-analysis of published randomized trials. Curr Med Res Opin 2007; 23: 601-8.
28. Netland PA, Landry T, Sullivan EK, et al. Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension, Am J Ophthalmol 2001; 132: 472-84.
29. Topouzis F, Melamed S, Danesh-Meyer H, et al. The international travoprost/timolol study group. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol0.5% to once-daily latanoprost0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Glaucoma 2007; 2: 17: 183-90.
30. Caro JJ. Pharmaco-economic analyses using discrete event simulation. Pharmacoeconomics 2005; 23: 323-32.
31. Denis P, Launois R, Devaux M, Berdeaux G. Medical outcomes of glaucoma therapy from a nationwide representative survey. Clin Drug Invest 2004; 24: 3430-52.
32. Nordmann JP, Lafuma A, Pradet S, Berdeaux G. Clinical outcomes of glaucoma treatments over a patient lifetime : a Markov model. J Glaucoma 2005; 14: 463-9.
33. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177-85.